# Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

> **NCT00179725** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celgene Corporation** · enrollment: 60 (—)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** CC-5013
- **DRUG:** liposomal doxorubicin

## Key facts

- **NCT ID:** NCT00179725
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 60 (—)
- **Last updated:** 2006-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00179725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00179725, "Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00179725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*